Cargando…

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We als...

Descripción completa

Detalles Bibliográficos
Autores principales: Docherty, Kieran F., Welsh, Paul, Verma, Subodh, De Boer, Rudolf A., O’Meara, Eileen, Bengtsson, Olof, Køber, Lars, Kosiborod, Mikhail N., Hammarstedt, Ann, Langkilde, Anna Maria, Lindholm, Daniel, Little, Dustin J., Sjöstrand, Mikaela, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Schou, Morten, Solomon, Scott D., Sattar, Naveed, Jhund, Pardeep S., McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508991/
https://www.ncbi.nlm.nih.gov/pubmed/35971840
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060511
_version_ 1784797137398136832
author Docherty, Kieran F.
Welsh, Paul
Verma, Subodh
De Boer, Rudolf A.
O’Meara, Eileen
Bengtsson, Olof
Køber, Lars
Kosiborod, Mikhail N.
Hammarstedt, Ann
Langkilde, Anna Maria
Lindholm, Daniel
Little, Dustin J.
Sjöstrand, Mikaela
Martinez, Felipe A.
Ponikowski, Piotr
Sabatine, Marc S.
Morrow, David A.
Schou, Morten
Solomon, Scott D.
Sattar, Naveed
Jhund, Pardeep S.
McMurray, John J.V.
author_facet Docherty, Kieran F.
Welsh, Paul
Verma, Subodh
De Boer, Rudolf A.
O’Meara, Eileen
Bengtsson, Olof
Køber, Lars
Kosiborod, Mikhail N.
Hammarstedt, Ann
Langkilde, Anna Maria
Lindholm, Daniel
Little, Dustin J.
Sjöstrand, Mikaela
Martinez, Felipe A.
Ponikowski, Piotr
Sabatine, Marc S.
Morrow, David A.
Schou, Morten
Solomon, Scott D.
Sattar, Naveed
Jhund, Pardeep S.
McMurray, John J.V.
author_sort Docherty, Kieran F.
collection PubMed
description Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. METHODS: Iron deficiency was defined as a ferritin level <100 ng/mL or a transferrin saturation <20% and a ferritin level 100 to 299 ng/mL. Additional biomarkers of iron metabolism, including soluble transferrin receptor, erythropoietin, and hepcidin were measured at baseline and 12 months after randomization. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. RESULTS: Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P<0.0001). The effect of dapagliflozin on the primary outcome was consistent in iron-deficient compared with iron-replete patients (hazard ratio, 0.74 [95% CI, 0.58–0.92] versus 0.81 [95% CI, 0.63–1.03]; P-interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. CONCLUSIONS: Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
format Online
Article
Text
id pubmed-9508991
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95089912022-10-03 Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF Docherty, Kieran F. Welsh, Paul Verma, Subodh De Boer, Rudolf A. O’Meara, Eileen Bengtsson, Olof Køber, Lars Kosiborod, Mikhail N. Hammarstedt, Ann Langkilde, Anna Maria Lindholm, Daniel Little, Dustin J. Sjöstrand, Mikaela Martinez, Felipe A. Ponikowski, Piotr Sabatine, Marc S. Morrow, David A. Schou, Morten Solomon, Scott D. Sattar, Naveed Jhund, Pardeep S. McMurray, John J.V. Circulation Original Research Articles Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. METHODS: Iron deficiency was defined as a ferritin level <100 ng/mL or a transferrin saturation <20% and a ferritin level 100 to 299 ng/mL. Additional biomarkers of iron metabolism, including soluble transferrin receptor, erythropoietin, and hepcidin were measured at baseline and 12 months after randomization. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death. RESULTS: Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P<0.0001). The effect of dapagliflozin on the primary outcome was consistent in iron-deficient compared with iron-replete patients (hazard ratio, 0.74 [95% CI, 0.58–0.92] versus 0.81 [95% CI, 0.63–1.03]; P-interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. CONCLUSIONS: Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124. Lippincott Williams & Wilkins 2022-08-16 2022-09-27 /pmc/articles/PMC9508991/ /pubmed/35971840 http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060511 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
spellingShingle Original Research Articles
Docherty, Kieran F.
Welsh, Paul
Verma, Subodh
De Boer, Rudolf A.
O’Meara, Eileen
Bengtsson, Olof
Køber, Lars
Kosiborod, Mikhail N.
Hammarstedt, Ann
Langkilde, Anna Maria
Lindholm, Daniel
Little, Dustin J.
Sjöstrand, Mikaela
Martinez, Felipe A.
Ponikowski, Piotr
Sabatine, Marc S.
Morrow, David A.
Schou, Morten
Solomon, Scott D.
Sattar, Naveed
Jhund, Pardeep S.
McMurray, John J.V.
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
title Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
title_full Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
title_fullStr Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
title_full_unstemmed Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
title_short Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
title_sort iron deficiency in heart failure and effect of dapagliflozin: findings from dapa-hf
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508991/
https://www.ncbi.nlm.nih.gov/pubmed/35971840
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060511
work_keys_str_mv AT dochertykieranf irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT welshpaul irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT vermasubodh irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT deboerrudolfa irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT omearaeileen irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT bengtssonolof irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT køberlars irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT kosiborodmikhailn irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT hammarstedtann irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT langkildeannamaria irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT lindholmdaniel irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT littledustinj irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT sjostrandmikaela irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT martinezfelipea irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT ponikowskipiotr irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT sabatinemarcs irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT morrowdavida irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT schoumorten irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT solomonscottd irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT sattarnaveed irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT jhundpardeeps irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf
AT mcmurrayjohnjv irondeficiencyinheartfailureandeffectofdapagliflozinfindingsfromdapahf